Olomorasib

Olomorasib
Clinical data
Other names	LY3537982
Identifiers
	IUPAC name (4M)-2-amino-4-[(4aS)-8-chloro-10-fluoro-12-oxo-3-(prop-2-enoyl)-2,3,4,4a,5,6-hexahydro-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-1-benzothiophene-3-carbonitrile;
CAS Number	2649788-46-3;
PubChem CID	156472638;
ChemSpider	115009373;
UNII	C2VJ83PSN7;
KEGG	D12853;
Chemical and physical data
Formula	C25H19ClF2N4O3S
Molar mass	528.96 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=C(SC5=C(C=C4)F)N)C#N)Cl;
	InChI InChI=1S/C25H19ClF2N4O3S/c1-2-18(33)31-6-7-32-12(11-31)5-8-35-22-14(25(32)34)9-17(28)20(21(22)26)13-3-4-16(27)23-19(13)15(10-29)24(30)36-23/h2-4,9,12H,1,5-8,11,30H2/t12-/m0/s1; Key:OZUPICRWMLEFCS-LBPRGKRZSA-N;

Olomorasib (LY3537982) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS), an oncogene commonly present in several forms of cancer. It is in early stage clinical trials against lung and colorectal cancers and advanced solid tumors.^[1]^[2]^[3]^[4]^[5]

Other namesLY3537982

CAS Number

2649788-46-3

PubChem CID

156472638

ChemSpider

115009373

Quick facts Clinical data, Other names ...

Close

[1]

[2]

[3]

[4]

[5]

Olomorasib

See also

References

Related Articles